Pursuing Unexplored Targets to halt and reverse fibrotic activity in the clinic
Mediar is pioneering a new approach to fibrosis treatment that aims to halt the disease at a different source – the myofibroblast, the key pathogenic cell in fibrosis that drives scarring, disease progression, and ultimately organ failure.
New perspective. Novel targets. Clinical trials.
The myofibroblast is responsible for depositing collagen, extracellular matrix, and maintaining the pro-fibrotic micro-environment in the body. A new class of targets known as fibrotic mediators control and activate the pathogenic myofibroblast. By neutralizing these mediators with novel antibodies, we can disable the myofibroblast, slow fibrosis, and enabling healing.
Mediar is embarking on Phase 2 clinical studies in fibrosing diseases to bring new potential options for patients and their caregivers.
Fearlessly Charting a Course Toward Patient Impact
Mediar’s team of industry-leading researchers & clinicians combines deep fibrosis expertise, antibody engineering knowledge, and clinical trial expertise to advance novel programs through approval. We have deep expertise in running late-stage clinical programs in fibrosis and related indications that include IPF, liver, and other areas.
Passionately Powered by Science for Patient Impact
